Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
NB

NASDAQ · NBP

NovaBridge Biosciences American Depositary Shares

Healthcare · Biotechnology

$1.59

Down-$0.10 (-5.92%)

Updated Sep 12, 2026, 11:06 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
449.54M
P/E ratio
-58.83
Dividend yield
0.00%
52-week range
$1.46 – $3.55
Volume
252.83K
Avg. volume
1.21M

Price performance

NBP price history

1M range · 20 trading sessions · Daily adjusted prices

NBP closed at $1.59 after 20 trading sessions, down 18.88% for the selected period.

Last close
$1.59
Period change
-18.88%
Period low
$1.59
Period high
$2.00
Daily close
View OHLC price history
NBP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$1.70$1.71$1.58$1.59252.83K
Sep 10, 2026$1.67$1.70$1.6595$1.69129.33K
Sep 9, 2026$1.77$1.80$1.68$1.70309.33K
Sep 8, 2026$1.79$1.825$1.75$1.78127.01K
Sep 4, 2026$1.79$1.82$1.77$1.8071.52K
Sep 3, 2026$1.79$1.815$1.755$1.80165.45K
Sep 2, 2026$1.72$1.80$1.72$1.79183.46K
Sep 1, 2026$1.81$1.835$1.705$1.73491.17K
Aug 31, 2026$1.81$1.865$1.80$1.82273.73K
Aug 28, 2026$1.90$1.90$1.79$1.84193.74K
Aug 27, 2026$1.92$1.935$1.865$1.89249.15K
Aug 26, 2026$1.94$1.945$1.85$1.87218.45K
Aug 25, 2026$1.89$1.99$1.88$1.93410.64K
Aug 24, 2026$2.01$2.01$1.85$1.89271.7K
Aug 21, 2026$1.91$2.02$1.889$2.00443.08K
Aug 20, 2026$1.97$1.97$1.7801$1.91385.2K
Aug 19, 2026$1.89$1.98$1.89$1.98287.73K
Aug 18, 2026$1.94$1.94$1.86$1.89205.14K
Aug 17, 2026$1.92$2.005$1.91$1.93302.06K
Aug 14, 2026$1.92$1.97$1.83$1.96333.54K

Latest NBP news

The latest Smart Investors Daily articles mentioning NBP.

Stock researchCompany · Overview

NBP research

Overview

Company profile and research snapshot.

Company profile

NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$7.75
Implied upside
—
Analysts
—
NBP recent ratings
DateFirmRatingTarget
Aug 20, 2026HC Wainwright & Co.Buy—
Apr 8, 2026HC Wainwright & Co.Buy—
Mar 16, 2026HC Wainwright & Co.Buy—
Feb 6, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

NovaBridge Biosciences to Participate in September Investor Conferences

ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026: Conference details: Cantor 2026 Global Healthcare ConferenceFormat: Fireside Chat and one-on-one

Yahoo · Feb 19, 2026

NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform

Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge subsidiary company Visara, Inc., will also join the Board

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By